Ketamine-Assisted Psychotherapy (KAP): APA 2026 Notes

TL;DR

• Ketamine-assisted psychotherapy (KAP) is ketamine + structured therapy — not just an infusion. The medicine creates a window of psychological openness; the therapy turns that window into lasting change.
• Many ketamine clinics don't offer this. They give an infusion and send you home. Researchers at APA 2026 argued this is a missed opportunity — and possibly a safety gap for patients processing trauma.
• KAP has three phases: preparation (education + intention-setting), the dosing session (with therapists present), and integration (psychotherapy in the days/weeks afterward).
• The dose matters. Lower-dose "psycholytic" KAP keeps the patient verbal and able to talk during the session. Higher-dose "psychedelic" KAP produces a deeper, more dissociative experience with integration happening afterward.
• Four case studies presented at APA 2026 show KAP working in real patients — depression with childhood trauma and borderline personality features, severe PTSD with suicidal behavior, treatment-refractory depression after 12 ECT sessions, and a religious 66-year-old finding meaning through archetypal imagery.
• Insurance often won't cover KAP even when it works. This is a documented access barrier and one of the reasons patients turn to cash-pay or telehealth programs.

This is part of a series of patient-facing posts translating what was discussed at the American Psychiatric Association's 2026 Annual Meeting in San Francisco.

What is ketamine-assisted psychotherapy?

Most patients hear "ketamine therapy" and picture a clinic with IV bags and recliners. A person gets an infusion, lies there for 40 minutes, and goes home. That's a real treatment model — and for many patients, particularly with severe depression, it provides measurable benefit.

But ketamine-assisted psychotherapy (KAP) is something different. The medicine is the same. Everything around it is structured to make the experience therapeutically meaningful:

• Before the session: education about what to expect, intention-setting, building a relationship with the therapist(s) who will be present
• During the session: one or two therapists in the room (along with a medical provider monitoring vitals), eye mask and music to focus inward, a deliberate environment designed to feel safe and contained
• After the session: therapy sessions in the days and weeks afterward to make sense of what came up

This is the model used in MDMA research, psilocybin research, and the most established ketamine-therapy programs. The premise: the medicine alone is doing something useful, but the medicine plus structured therapy does something more durable.

At APA 2026, a session led by Fernando Espi Forcen (McLean Hospital / Harvard Medical School), Albert Yeung (Mass General / Harvard Medical School), Steven Taylor, and Juliana Zambrano Navia (Mass General / Harvard) walked the audience through what KAP actually looks like in practice — and what it can do for patients who have not responded to standard psychiatric care.

Why "set and setting" matters more than people think

A phrase that has carried over from the 1960s psychedelic research and is still used today: "set and setting."

• Set is what the patient brings into the session — their mental state, expectations, mood, beliefs, motivations
• Setting is the physical environment — the room, the people, the lighting, the music

Decades of psychedelic research show these factors shape what the experience actually does to the brain and the long-term outcome, not just the subjective feeling during the session. Two patients with identical doses of ketamine can have wildly different therapeutic results depending on what they bring in (set) and what surrounds them (setting).

This is why a KAP setup looks more like a comfortable living room than a hospital infusion bay. A patient who feels safe and curious is dramatically more likely to have a productive session than a patient who feels rushed or clinical.

It's also why telehealth-supervised at-home ketamine therapy makes sense for many patients — for a lot of people, the most therapeutically optimal "setting" is their own bedroom, with their own music, in their own home.

The two main KAP models

KAP isn't one thing. The dose and route of administration define two distinct experiences:

Psycholytic KAP (lower dose)

• Doses: sublingual 25–200 mg, or IV under 0.3 mg/kg
• What it produces: mild perceptual shifts, the patient stays largely verbal and able to talk
• What the brain is doing: decreased "default mode network" activity (the brain's self-referential network), heightened emotional access
• What it's good for: when the goal is to work through specific material together with a therapist, in real time, during the session

Psychedelic KAP (higher dose)

• Doses: IV infusion above 0.5 mg/kg
• What it produces: deeper dissociation, "ego dissolution," out-of-body experiences, mystical content
• What the brain is doing: more profound disruption of the default mode network; what researchers call a "high-entropy" brain state
• What it's good for: when the patient is stuck in entrenched patterns of thinking that the higher-dose experience can interrupt. Integration happens after the session, since the patient typically can't engage in conversation during it.

Both models are legitimate. The choice depends on the patient, the condition, and the therapist's experience.

A KAP case study: depression, trauma, and borderline personality features

Albert Yeung presented a detailed case study — published in 2025 in the Journal of Personality Disorders — of a graduate student in her 30s with a history of childhood neglect and trauma. Her presentation:

• "I am depressed all my life"
• Anhedonia, hopelessness, persistent suicidal thoughts
• Had a designated date to attempt suicide if treatment didn't work
• History of treatment with multiple antidepressants, mood stabilizers, stimulants — without significant improvement
• Diagnosed with generalized anxiety disorder and borderline personality disorder

Her KAP protocol unfolded across three phases:

Early phase (sessions 1–3, sublingual 100–300 mg)

What came up:

• Intense emotional release: crying, sobbing, screaming
• Previously inaccessible traumatic memories emerging — high-school inappropriate touching, near sexual assaults in college
• Fear of being abandoned by the therapist
• Dark imagery: "bottom of the ocean," polluted earth, visualizing her husband finding her body
• Underlying integration themes: emotional abuse from her father, mother "not there," violation by a soccer coach

After 3 sessions: marked improvement in emotional regulation and calmness.

Middle phase (sessions 4–6, intramuscular ketamine 25–40 mg)

• ≥50% reduction in anxiety, depression, and suicidality scores
• Suicidal thoughts resolved
• Sessions still surfaced difficult material ("parents' basement" imagery) but it was less overwhelming
• Integration themes: insight into her parents' limitations, shift toward self-agency
  • "I need to get better… getting even is not my priority."
  • "Being a grown-up is seeking your own peacefulness and identity."

Late phase (sessions 7–9)

• Anxiety and depression reduced to ~1/3 of baseline
• "Vacation-like" experiences, themes of rebuilding and healing
• Ego dissolution and spiritual content: "Do I exist?" "I am a plant… we are all from the soil."
• 8th session: "I feel like I'm at a party" — first time the experience wasn't centered on self

Follow-up

• 4 months: "I can now process things… in the past they would have been repressed." Insight into anxious attachment, fear of joy and love. No more suicidal thoughts.
• 6 months: no suicidal ideation, increased spirituality, compassion, connectedness. Residual symptoms (some anxiety, low appetite) but functionally improved.

What the case illustrates: ketamine alone — without the therapeutic frame around it — would not have produced this kind of integration of childhood trauma. The medicine made the material accessible. The therapy made it usable.

KAP for severe suicidal behavior: a second case

Espi Forcen presented a 2022 case study (Palliative and Supportive Care) of a 37-year-old man with:

• Major depressive disorder
• PTSD from family suicides
• Had refused ECT
• Made a plan to shoot himself, wrote suicide notes

He received ketamine combined with meaning-centered psychotherapy — a specific therapy framework originally developed for cancer patients facing existential distress. Outcome:

• Remission of suicidal ideation
• 6-month follow-up: doing well

For patients who decline ECT but have not responded to other interventions, KAP — particularly when paired with a therapy approach addressing meaning and existential concerns — can be a life-changing option.

KAP after 12 sessions of ECT: a third case

A 2023 case (Zambrano & Espi Forcen, Journal of Clinical Psychopharmacology) of a 51-year-old woman:

• Major depressive disorder + PTSD
• Serious overdose attempt
• 12 sessions of ECT without sustained benefit
• Then started IV ketamine + KAP during inpatient stay
• Remission of suicidal thoughts

The honest postscript: insurance would not cover ketamine after discharge. A patient who responded to a treatment then could not maintain it. This is the scaling and access problem the field has been openly discussing — patients who improve on these therapies lose access when they leave a structured setting.

KAP and cultural context

One of the most important threads in the session: KAP research has been conducted overwhelmingly in white, English-speaking, well-resourced populations.

Espi Forcen and Zambrano have been publishing on KAP among Latinx patients (e.g., Zambrano et al., J Immigr Minor Health 2025). What they've found:

• Findings from majority-white trials are not automatically representative
• Cultural context shapes how the ketamine experience is interpreted
• Religious and family meaning systems can be central to what the patient processes
• Group KAP formats may align well with collectivist cultural frameworks

A striking case from Espi Forcen's deck: a 66-year-old Italian-American Catholic woman taking ketamine for depression at an inpatient unit. She had no prior psychedelic experience. During her session:

• She held a Virgin Mary ring on her finger and a Catholic prayer stamp on her chest
• During the session: felt the presence of the Virgin Mary (mother / divine / idealized feminine), Michael the Archangel (protector / hero), Jesus Christ (savior / redeemer), the goddess Isis, Mother Earth below
• Integration themes: reconnecting with her daughter, the role of being a grandmother

The same medication. The same dose. But the content of her experience was shaped by her religious life, and the therapeutic outcome — finding new meaning in her role as a grandmother — emerged from material that wouldn't have surfaced in a secular setting.

This is why patient-matched therapy frameworks matter in KAP. Not every patient needs or wants Jungian interpretation or religious framing. But the therapist's flexibility to meet the patient where they are is part of what makes KAP different from a simple infusion.

What about Jungian dream interpretation?

One distinctive thread in Espi Forcen's work: applying the framework of Carl Jung (the early-20th-century psychiatrist who emphasized symbolic dreams, archetypes, and the unconscious) to interpret ketamine experiences.

The premise: ketamine produces vivid, dreamlike imagery that often contains universal symbolic content — what Jung called archetypes. Common psychedelic archetypes the field has documented:

• The rebirth
• The hero
• The wise old person
• The trickster
• The mother
• The idealized feminine and masculine

Patients often describe their experiences using these same archetypal images, even when they have no prior exposure to Jungian thinking. Whether this reflects something universal about the human unconscious (Jung's view) or simply that these images are widely embedded in culture is a question therapists can hold lightly. What matters clinically is that the imagery is workable — the patient can journal about it, interpret it, and use it to access material they hadn't been able to talk about in conventional therapy.

This won't be everyone's cup of tea. Some patients prefer a CBT-style approach, focused on concrete thoughts and behavior. Others find a more symbolic or Jungian framework profoundly clarifying. Both can be valid integration approaches.

How this fits with at-home ketamine therapy

At Isha Health, we run a physician-led at-home ketamine therapy program. Patients work with a physician via video, complete dosing sessions at home with telehealth supervision, and have access to integration support.

The KAP framework discussed at APA 2026 informs how we think about this work:

• Preparation matters more than the medicine. What we do in the consultation, the intention-setting, the planning for the session — that work shapes the outcome.
• The session environment matters. Your bedroom can be a better therapeutic "setting" than a clinical infusion center.
• Integration is where the change becomes lasting. A productive session followed by no integration is a missed opportunity.

Not every Isha patient needs intensive integration with a therapist — some come to us already with a therapist and need ketamine as the missing piece, others need a more structured supportive framework. The protocol is matched to the patient.

What this means for you as a patient

If you're considering ketamine therapy, a few practical questions to ask any program:

1. What happens before the session? A 10-minute intake form is not the same as a 60-minute preparation conversation.
2. Who's there during the session? "Just take the medicine" programs are different from programs with monitoring and therapeutic presence.
3. What does integration look like? Some programs include integration; others leave it to you. Both can work, but you should know which model you're getting.
4. Is there a relationship with a therapist outside the session? This matters most for patients whose underlying issue is trauma, complex grief, identity work — not just neurochemical depression.
5. What's the dose model? Lower-dose psycholytic vs. higher-dose psychedelic protocols produce different experiences and require different integration approaches.

KAP isn't right for everyone, and it isn't always necessary. For many patients with straightforward depression, a structured infusion or oral protocol with light integration is enough. But for patients carrying trauma, complex grief, or stuck patterns that talk therapy alone hasn't moved — the therapy + medicine combination is where the data on lasting benefit is strongest.

Sources cited

• Yeung A et al. Journal of Personality Disorders 2025 — KAP case study in BPD and depression
• Espi Forcen F, Marengo L, Behn M. Palliative and Supportive Care 2022 — Ketamine-assisted meaning-centered psychotherapy for severe suicidal behavior
• Zambrano J, Espi Forcen F. Journal of Clinical Psychopharmacology 2023 — KAP for hospitalized PTSD + MDD
• Zambrano J, Espi Forcen F, Hidalgo J, King F. Journal of Immigrant and Minority Health 2025 — Group psychedelic therapy for Latinx immigrants
• Espi Forcen F, Nyer M. Psychiatric Annals 2022 — Ketamine with psychotherapy for depression
• Dore J et al. Journal of Psychoactive Drugs 2019 — Ketamine-assisted psychotherapy framework
• Cristea IA et al. JAMA Psychiatry 2017 — Efficacy of psychotherapies for borderline personality disorder
• Carhart-Harris RL, Goodwin GM. Neuropsychopharmacology 2017 — Differential serotonergic actions of SSRIs and psychedelics
• Kavalali ET, Monteggia LM. Trends in Neurosciences 2012 — Synaptic mechanisms of ketamine's antidepressant action

---

Related Articles

• APA 2026 Annual Meeting Recap
• Ketamine for OCD: Stanford Trial Shows 3-Week Effect
• The 40-Year Antidepressant Plateau
• How does ketamine work?
• How does ketamine-assisted psychotherapy work?

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.